【摘要】 二肽基肽酶4抑制剂(DPP-4i)是一种新型口服降糖药,在糖尿病联合治疗中优势明显,是近年来使用率增长最快的口服降糖药物。DPP-4i在心血管死亡、心肌梗死、卒中事件中不增加心血管复合终点的风险,其作用机制可能是上调基质细胞衍生因子1α、减少可溶性细胞间黏附分子1表达水平,以降低炎症和心肌纤维化作用。不同DPP-4i对心力衰竭的影响不同,肾脏钠/氢交换因子3可能是其潜在的保护靶点。近年来,利格列汀以其独特的优势,优先在DKD患者中使用。更多还原

【Abstract】 Dipeptidyl peptidase 4 inhibitor(DPP-4i)is a new type of oral hypoglycemic agent. The utilization of DPP-4i is growing rapidly in recent year with advantages in the combination therapy of diabetes.DPP-4i does not increase the risk of cardiovascular compound endpoints in cardiovascular death,myocardial infarction and stroke events. The mechanism may be up-regulating stromal cell-derived factor 1(SDF-1α)and inhibiting the expression of soluble intercellular adhesion molecule 1 to reduce inflammation and fibrosis.Different DPP-4i have different effects on heart failure,of which,renal sodium hydrogen exchanger 3 may be a potential protection target. With its unique advantages,linagliptin is preferred for patients with diabetic kidney disease.更多还原